{"nctId":"NCT00332488","briefTitle":"Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2004-12"},"conditions":["Diabetes Mellitus, Type 2"],"count":547,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Technosphere Insulin"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin & Secretagogues"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: Technosphere Insulin & Metformin"]}],"interventions":[{"name":"Technosphere Insulin","otherNames":[]},{"name":"Metformin & Secretagogues","otherNames":[]},{"name":"Technosphere Insulin & Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Non-smokers with clinical diagnosis of Type 2 diabetes mellitus for \\>or= to 6 months\n* Stable regimen of metformin for \\> or = to 1000mg/day or maximum tolerated dose) and a secretagogue \\< or = 1/2 the maximum manufacturer-recommended daily dose without any dose adjustments within the preceding 6 wks.\n* Fixed dose combination products of metformin and sulfonylurea are acceptable as long as each individual dose meets inclusion criteria\n* HbA1c \\>or= to 7.5% and \\< or= to 11.0%\n* BMI \\< or = to 40kg/m2.\n* FEV1\\> or = to 70%, Total Lung capacity and \\> or =80% DLco \\> or= to 70%\n\nExclusion Criteria:\n\n* Treatment with any type of anti-diabetic therapy, other than metformin \\& secretagogues within the preceding 12 weeks\n* Serum creatinine \\> 1.4mg/dL in female subjects and \\>1.5mg/dL in male subjects\n* History of chronic obstructive pulmonary disease, clinically proven asthma and/or any other clinically important pulmonary function testing and/or radiologic findings\n* Evidence of serious complications of diabetes (e.g. autonomic neuropathy)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"-0.78"},{"groupId":"OG001","value":"-0.70","spread":"-0.70"}]}]}]},{"type":"SECONDARY","title":"Difference in Change From Baseline for HbA1c Between TI Alone and Metformin+Secretagogue","description":"(Change from baseline within TI Alone) minus (change from baseline within metformin + secretagogue)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"1.3"},{"groupId":"OG001","value":"-0.76","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Week 24 (Subjects Who Stayed on Original Treatment)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.82","spread":"1.114"},{"groupId":"OG001","value":"-1.23","spread":"1.080"},{"groupId":"OG002","value":"-1.68","spread":"1.014"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":181},"commonTop":["HYPOGLYCAEMIA","COUGH","NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION"]}}}